Journal of Clinical Pharmacy and Therapeutics最新文献

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148078550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148074986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mulberroside C Attenuates LPS-Induced Acute Lung Injury in Mice via Anti-Inflammatory and Antioxidant Mechanisms","authors":"Fangfang Yang,&nbsp;Xiaobing Xin,&nbsp;Lidan Li,&nbsp;Lili Zhu,&nbsp;Jinjing Li,&nbsp;Qiaoyan Li,&nbsp;Yuting Zhu,&nbsp;Xiaohua Wang","doi":"10.1155/jcpt/5519072","DOIUrl":"https://doi.org/10.1155/jcpt/5519072","url":null,"abstract":"<p>Acute lung injury (ALI) is a pulmonary disease exhibited by local inflammation, which can lead to hypoxemia, pulmonary edema, and respiratory failure, and lacks targeted treatment strategies. Mulberroside C (Mul C) is a bioactive phytochemical isolated from <i>Mori Cortex Radicis (MCR)</i>. In this research, we developed a murine model of lipopolysaccharide (LPS)-induced ALI. Mul C administration significantly reduced the lung wet/dry weight ratio and increased body weight in LPS-induced ALI mice, improved pathological changes in pulmonary tissue, alleviated pulmonary edema, and inhibited inflammatory response. Mul C treatment reduced the concentration of malondialdehyde (MDA) in murine pulmonary tissue with ALI, while boosting glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activity in lung tissue. In addition, Mul C had strong binding with NF-κB p65 and Nrf2 receptor proteins and upregulation of Nrf2 and downregulation of NF-κB p65 expression in pulmonary tissue. These findings suggest that Mul C shows protective effects in a pretreatment mouse model of LPS-induced ALI.</p>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5519072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Gastrointestinal Adverse Events in Cancer Patients on Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","authors":"Zhongli Liao,&nbsp;Xiaogang Hu,&nbsp;Shishi Yu,&nbsp;Jiong Wang,&nbsp;Bowen Deng,&nbsp;Fei Ao,&nbsp;Jian Yang","doi":"10.1155/jcpt/7614368","DOIUrl":"https://doi.org/10.1155/jcpt/7614368","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Immune checkpoint inhibitors (ICIs) have improved the survival rates of cancer patients. However, ICIs often cause gastrointestinal adverse events (AEs). This study aims to assess the risk of gastrointestinal AEs associated with ICIs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A comprehensive search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library databases to identify eligible phase III or phase IV, double-blind randomized controlled trials (RCTs) investigating gastrointestinal AEs (nausea, vomiting, colitis, abdominal pain, constipation, and diarrhea) in cancer patients treated with ICIs, published before December 3, 2024. References were managed using EndNote X21, and all statistical analyses were performed in R (Version 4.3.3). The pooled incidence of gastrointestinal AEs was estimated using a random-effects model. Subgroup analyses were performed according to predefined study designs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After excluding studies that did not meet the criteria, 10 RCTs were eligible for the meta-analysis. Diarrhea was the most common low-grade gastrointestinal AE, with an incidence of 18.862% (95% confidence interval [CI] = 14.920%–23.845%), followed by nausea (10.798% [95% CI = 7.781%–14.983%]) and vomiting (6.454% [95% CI = 3.945%–9.527%]). Among high-grade gastrointestinal AEs, diarrhea and colitis were the most common, with incidences of 3.719% (95% CI = 1.788%–6.314%) and 2.668% (95% CI = 1.590%–4.479%), respectively. Additionally, cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors, either alone or in combination with PD-1 inhibitors, were associated with a significantly higher risk of diarrhea and colitis compared to programmed cell death protein 1 (PD-1) inhibitors alone.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Gastrointestinal AEs are relatively common during ICI therapy. Monitoring and managing these events, especially diarrhea and colitis, are crucial to improving treatment efficacy in cancer patients, especially those receiving CTLA-4 inhibitors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/7614368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Validation of the Ferroptosis-Related Gene SLC2A1 as a Novel Prognostic Biomarker for Osimertinib Resistance in LUAD","authors":"Lixia Zhang,&nbsp;Erteng Jia,&nbsp;Haoyu Wang,&nbsp;Junda Chang,&nbsp;Li Li,&nbsp;He Zhang,&nbsp;Xiao Liang,&nbsp;Hao Zhang","doi":"10.1155/jcpt/3169792","DOIUrl":"https://doi.org/10.1155/jcpt/3169792","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Osimertinib shows remarkable efficacy as a first-line therapy for lung adenocarcinoma (LUAD), yet acquired resistance remains a major challenge. Ferroptosis dysregulation has emerged as a key contributor to drug resistance, highlighting ferroptosis-associated genes as potential biomarkers and therapeutic targets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Ferroptosis-related osimertinib resistance genes were identified through integrated TCGA and GEO analyses, and a prognostic model was constructed using Cox and LASSO regression. Drug-response profiles, immune infiltration patterns, and clinical associations were systematically evaluated. Functional experiments were conducted to elucidate the role of SLC2A1 in osimertinib resistance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A three-gene ferroptosis-associated signature (SLC2A1, LIFR, and GDF15) was established with high prognostic accuracy and independence. Low-risk patients showed greater chemotherapy sensitivity, whereas high-risk patients exhibited increased M0/M1 macrophage and CD8⁺ T-cell infiltration. High SLC2A1 expression was associated with reduced infiltration of antitumor lymphocytes—including naïve CD8⁺ T cells, Th17, Tfh, MAIT cells, B cells, γδT cells, and CD4⁺/CD8⁺ T cells—and increased levels of exhausted T cells, regulatory T cells, Th1/Tem cells, and myeloid-derived populations (DCs, monocytes, macrophages, and neutrophils). Clinical cohort validation confirmed the prognostic relevance of these genes. Mechanistically, SLC2A1 enhanced osimertinib resistance by activating the SLC7A11/GPX4 antioxidant axis and suppressing lipid peroxidation, thereby promoting ferroptosis evasion and reshaping an immunosuppressive tumor microenvironment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This study reveals the clinical and biological significance of ferroptosis-related resistance genes in LUAD and identifies a previously unrecognized mechanism through which SLC2A1 drives osimertinib resistance by promoting ferroptosis escape and reshaping the immunosuppressive tumor microenvironment. These findings highlight SLC2A1 as a promising therapeutic target for overcoming resistance and improving precision treatment strategies in LUAD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/3169792","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacist Involvement in Chemotherapy Induced Nausea and Vomiting Management: A Meta-Analysis","authors":"Xinmiao Lin,&nbsp;Lirong Zhang,&nbsp;Pingping Peng,&nbsp;Mumu Xie,&nbsp;XiaoXia Wei,&nbsp;Hong Sun,&nbsp;Jiaqin Cai","doi":"10.1155/jcpt/8267674","DOIUrl":"https://doi.org/10.1155/jcpt/8267674","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Most antineoplastic drugs are highly toxic and can cause drug-related gastrointestinal reactions. This review aimed to critically appraise the impact of clinical pharmacists in reducing the intensity of nausea and vomiting following chemotherapy in cancer patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A search was conducted to retrieve studies from eight databases that assessed the extent of pharmacist intervention in relieving nausea and vomiting after chemotherapy in cancer patients from construction to February 2024.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3077 records were retrieved, of which 20 met the inclusion criteria. The results demonstrated that the involvement of clinical pharmacists in the management of CINV in oncology patients was effective in increasing the rate of complete control of acute (<i>p</i> &lt; 0.001, RR = 1.21 [1.11–1.32]) and delayed (<i>p</i> &lt; 0.001, RR = 1.28 [1.02–1.59]) vomiting in chemotherapy patients. The incidence of nausea (<i>p</i> &lt; 0.001, RR = 0.77 [0.69–0.85]) and delayed nausea (<i>p</i> &lt; 0.001, RR = 0.67 [0.53–0.85]) in chemotherapy patients was also effectively mitigated. There was a significant improvement in patient adherence to oncology treatment (<i>p</i> &lt; 0.001, OR = 6.51 [3.18–13.35]).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Clinical pharmacists’ involvement in the management of CINV in patients undergoing cancer chemotherapy resulted in a reduction in the incidence of nausea and vomiting and improved patient adherence to treatment. The involvement of clinical pharmacists in the management of chemotherapy-induced nausea and vomiting, either directly or as a key member of the multidisciplinary oncology team, is of significant importance.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/8267674","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adverse Drug Events Associated With Selective Serotonin Reuptake Inhibitor Use During Pregnancy: A Pharmacovigilance Analysis Based on Real-World Data","authors":"Lu Wang,&nbsp;Rui Xiong,&nbsp;Hengxu Liu,&nbsp;Shipeng Zhang,&nbsp;Yongtao Tong,&nbsp;Guangtao Hu,&nbsp;Xiaodan Lai","doi":"10.1155/jcpt/2842468","DOIUrl":"https://doi.org/10.1155/jcpt/2842468","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Purpose</h3>\u0000 \u0000 <p>The study aims at providing valuable insights of safety of SSRI during pregnancy that assist the surveillance and possibly a timely intervention, by exploring the serious adverse drug events (ADEs) of SSRIs during pregnancy by conducting a pharmacovigilance analysis based on FDA adverse event reporting system (FAERS), and investigating comprehensive influencing factors of ADEs in real-word settings.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The association between 5 commonly used SSRIs (i.e., paroxetine, fluoxetine, escitalopram, sertraline and citalopram) and ADEs was assessed by performing a disproportionality analysis. Cases were classified into serious and nonserious ADE groups based on their clinical outcomes, and their general characteristics were described. Influencing factors of occurrence of serious ADEs were identified through logistic regression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We first investigated ADEs associated with SSRI use during pregnancy based on real-world data. Our research highlights the clinical significance of proper SSRI option, depression severity and concomitant drug use in reducing serious ADEs.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/2842468","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Linezolid Dosing by Renal Function: A Population Pharmacokinetic Study","authors":"Khue N. Y. Ha,&nbsp;Ngan T. K. Tran,&nbsp;Cuc T. Nguyen,&nbsp;Thu T. A. Nguyen,&nbsp;Nhi T. L. Vu,&nbsp;Truc T. T. Nguyen,&nbsp;Cam T. N. Vo,&nbsp;Vy T. Lu,&nbsp;Quan D. Do,&nbsp;Diem N. Duong,&nbsp;Khanh H. T. Bui,&nbsp;Hoa D. Vu,&nbsp;Doan-Trang Dang-Nguyen","doi":"10.1155/jcpt/6640426","DOIUrl":"https://doi.org/10.1155/jcpt/6640426","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Linezolid is administered at a fixed dose of 600 mg twice daily for the treatment of Gram-positive infections. However, recent population pharmacokinetic studies reveal considerable interpatient variability, resulting in subtherapeutic or supratherapeutic drug exposures. This study aimed to describe the pharmacokinetics of linezolid in hospitalized infectious patients across varying degrees of renal function and propose optimized dosing strategies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Population pharmacokinetic modeling was performed using Monolix Version 2024R1. The model was evaluated using goodness-of-fit plots, bootstrap analysis, and prediction-corrected visual predictive checks. Appropriate dosing regimens for different levels of renal function and minimum inhibitory concentrations were proposed by Monte Carlo simulations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-five adult patients with a total of 178 linezolid concentration measurements were included. A two-compartment model with first-order absorption and linear elimination best described the pharmacokinetic data. Volume of distribution and clearances were scaled using an allometric weight model. In addition, creatinine clearance (CLcr) significantly affected linezolid clearance. Simulation results suggested that patients with CLcr ≤ 30 mL/min may require reduced doses (600–900 mg daily), whereas those with CLcr ≥ 110 mL/min may benefit from increased doses (600 mg every 8 h).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Individualization of linezolid dosing based on renal function is warranted. Therapeutic drug monitoring is recommended for patients with impaired or augmented renal clearance to optimize the therapeutic efficacy and minimize the risk of toxicity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/6640426","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147615173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers Associated With Treatment Nonadherence in Mexican Patients With Ulcerative Colitis: The Role of Medication Beliefs","authors":"Ana Fresán,&nbsp;Karen A. Yamamoto-Rodríguez,&nbsp;Katia M. Yamamoto-Rodríguez,&nbsp;Jesus K. Yamamoto-Furusho","doi":"10.1155/jcpt/9901738","DOIUrl":"https://doi.org/10.1155/jcpt/9901738","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The adherence to medical treatment is important in patients with inflammatory bowel disease (IBD) in order to maintain remission and avoid complications. The aim of this study was to identify the demographics, clinical features, and patients’ barriers associated with nonadherence to medical treatment in Mexican patients with ulcerative colitis (UC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This cross-sectional and comparative study included 121 patients with confirmed diagnosis of UC between August 2017 and January 2018. Patients’ barriers were assessed using the specific section of barriers of the Beliefs about Medicines Questionnaire (BMQ), and the Self-Efficacy for Appropriate Medication Use Scale (SEAMS) was used to assess treatment adherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>According to the BMQ barriers, 31.4% (<i>n</i> = 38) of the participants reported negative beliefs about treatment, 55.4% (<i>n</i> = 67) recall barrier, and 46.3% (<i>n</i> = 56) access barrier to medication. The mean score of the SEAMS was 30.0 points (S.D. = 7.0), and according to the cutoff point, we found that 50.4% (<i>n</i> = 61) of the participants were nonadherent to their current treatment. Recall barrier (OR = 7.6), negative beliefs about medication (OR = 6.6), and disease severity (OR = 5.9) were factors associated with medication nonadherence.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The frequency of medical treatment nonadherence was 50.4% in Mexican patients with UC, and the barriers associated were recall barrier, negative beliefs about medication, and disease severity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/9901738","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147567349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Pharmacist Interventions in a Brazilian Intensive Care Unit: An Eight-Year Retrospective Analysis","authors":"Cyntia Elizabeth Fonseca Bosco Galvão,&nbsp;Dayani Galato","doi":"10.1155/jcpt/5510996","DOIUrl":"https://doi.org/10.1155/jcpt/5510996","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To identify the pharmaceutical interventions carried out by the clinical pharmacy service in an adult intensive care unit and to evaluate their evolution over an 8-year period.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This descriptive study evaluated pharmaceutical interventions recorded between 2016 and 2023 in a general adult ICU of a public hospital in Brasília, Brazil. Data were collected from a clinical pharmacy database, including patient demographics, intervention types, acceptance rates, targeted professionals, and medications involved. Interventions were categorized and analyzed by age groups, year, and professional target.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 3582 interventions were performed in 663 patients, with an acceptance rate of 96%. The median patient age was 58 years, and 56.9% were male. The most frequent interventions were medication addition (23.5%), discontinuation (10.5%), and dosage increase (8.2%). Interventions predominantly targeted the medical team, with a shift from nursing staff in the service’s initial year. The main medications were antimicrobials (notably meropenem), anticoagulants (enoxaparin), and proton pump inhibitors (pantoprazole, omeprazole). Over time, a qualitative and quantitative change in intervention profiles was observed, with increased pharmacist participation in pharmacotherapy decisions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Pharmaceutical interventions in the ICU evolved towards greater involvement in pharmacotherapy management, predominantly directed at medical professionals. High acceptance rates indicate the integration of pharmacists into the multidisciplinary team. Further studies are recommended to explore the reduction in nursing-directed interventions and the impact on patient outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2026 1","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/jcpt/5510996","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147566518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}